Breakthrough joint replacement antibiotic study named Trial of the Year
A study investigating how effective additional antibiotics are in the prevention of post-joint surgery infection, undertaken by Alfred Health and Monash University, has been awarded this year’s prestigious Australian Clinical Trials Alliance (ACTA) Trial of the Year Award.
Deputy Director of Research in Infectious Diseases, Prof Trisha Peel, led the Australian Surgical Antibiotic Prophylaxis (ASAP) trial looking at whether adding a second antibiotic at the time of surgery, in addition to a standard course, helped prevent infection.
“While not common, post-surgery infection can be devastating and result in extended hospital admissions, further complications and mortality,” said Prof Peel.
“We wanted to examine whether the use of additional antibiotics, which is becoming more commonplace, actually helps or hinders the body’s ability to fight infection.”
Over 4200 patients were involved in the study, which ultimately found the addition of a secondary antibiotic did not protect against infection, and may have in fact led to more infections and more adverse reactions for patients.
“Our trial has answered the important about whether more antibiotics are better for our patients having joint replacement surgery: with the definitive answer a clear no”, said Prof Peel.
“Given the number of joint replacements performed in Australia and globally, this trial will have a significant impact on practice,” she said.
Prof Peel, said the award, which celebrates outstanding Australian achievements that advance clinical practice and save or improve patient lives, was a sign the trial was on track to guide practice.
“Being recognised in this way is a nice sign that your trial is being respected by your peers for being impactful and meaningful, and will hopefully improve patient outcomes in years to come,” she said.